Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Top Cited Papers
Open Access
- 20 October 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (11), 845-856
- https://doi.org/10.1038/nrc1739
Abstract
Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.Keywords
This publication has 119 references indexed in Scilit:
- Dissecting the metastatic cascadeNature Reviews Cancer, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Translating the Histone CodeScience, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989